For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

PNC-27: origin, structure and research history

Research Library › Peptide Fragments

PNC-27 is a synthetic 32-amino-acid chimeric peptide that joins residues 12–26 of the human p53 protein, the segment that binds the HDM-2 (MDM2) protein, to a 17-residue membrane-penetrating sequence based on penetratin. It was designed by Matthew Pincus, Josef Michl and colleagues at SUNY Downstate and the VA New York Harbor, and first reported in 2001. As of October 2026 it is not approved by the FDA or any other regulator, and the published evidence is preclinical only.

Key facts

TypeSynthetic 32-amino-acid chimeric peptide
SequencePPLSQETFSDLWKLL + KKWKMRRNQFWVKVQRG (p53 residues 12–26 + membrane-penetrating leader)
Derived fromThe HDM-2-binding region of the tumor-suppressor protein p53, fused to a penetratin-based sequence
First described2001, Proceedings of the National Academy of Sciences
Developed byMatthew R. Pincus, Josef Michl and colleagues, SUNY Downstate Medical Center and VA New York Harbor Healthcare System
Designed targetDesigned to bind HDM-2 (human MDM2); proposed in cell studies to bind HDM-2 located in cell membranes
Regulatory status (Oct 2026)Not FDA-approved; no registered human clinical trial; preclinical only

Who developed it

PNC-27 came out of a long collaboration led by Matthew R. Pincus, a pathologist and protein chemist at SUNY Downstate Medical Center in Brooklyn who also chaired pathology and laboratory medicine at the VA New York Harbor medical center, together with Josef Michl and co-workers [1, 2]. The group used computer-based conformational analysis of protein structures to pick short segments of p53 that might keep their natural shape when made as isolated peptides.

Their founding paper appeared in 2001 [1]. Later work was carried out with collaborators at Drexel University, Thomas Jefferson University and the New York Blood Center, and some authors list NomoCan Pharmaceuticals as an affiliation [3].

Structure and design

The tumor-suppressor protein p53 is held in check inside cells by a partner protein called MDM2 (HDM-2 in humans), which grips a short helical stretch near p53’s N-terminus. The Pincus group modeled that stretch and synthesized peptides matching p53 residues 12–26 (sequence PPLSQETFSDLWKLL), 12–20 and 17–26 [1]. A 2004 NMR study by the same group reported that the 12–26 segment holds a structure close to the one seen when p53 is bound to MDM2 [4].

To carry these fragments across cell membranes, each was attached at its C-terminus to a 17-residue leader, KKWKMRRNQFWVKVQRG, based on penetratin [1]. Penetratin is a cell-penetrating sequence first described in 1994 from the third helix of the Drosophila Antennapedia homeodomain [5]. The 12–26 version became PNC-27 (32 residues in total); the shorter 17–26 version is known as PNC-28 [2, 3]. The group later called the leader a “membrane residency peptide” [3].

The proposed mechanism changed over time. Rather than acting on p53 inside the cell, the 2010 work proposed that PNC-27 binds HDM-2 found in the outer membrane of transformed cells, based on cell-culture and binding experiments [6]. This remains a preclinical hypothesis.

Research history

  • 2001: First paper on penetratin-linked p53 peptides, including the 12–26 sequence later named PNC-27 [1]
  • 2004: NMR solution structure of the p53 12–26 peptide reported [4]
  • 2010: PNAS paper proposes membrane HDM-2 as the binding partner; MeSH adds PNC-27 as a supplementary concept [6, 7]
  • 2022: Structural and membrane study by the same group published in Biomedicines [3]

All published work on PNC-27 has been carried out in cell lines, isolated cells or animal models, mostly by the originating group and its collaborators. A SUNY Downstate faculty page has said the peptide would enter clinical trials, but no trial has been registered or reported [2].

Regulatory status as of October 2026

PNC-27 is not approved as a drug by the US Food and Drug Administration or by any other regulator. No investigational new drug program or human clinical trial for it has been publicly reported, and no study is listed on ClinicalTrials.gov. The evidence base is preclinical only.

PNC-27 is not named individually on the 2026 WADA Prohibited List, whose section S0 covers pharmacological substances not approved for human therapeutic use [8].

About this reference page

Kalibra Labs does not currently supply PNC-27. This page is published as a neutral scientific and regulatory reference. Browse the Peptide Fragments guide or the FDA Peptide Regulatory Tracker.

Frequently asked questions

What is PNC-27 made of?

PNC-27 joins residues 12–26 of the human p53 protein to a 17-residue membrane-penetrating sequence based on penetratin, giving a 32-amino-acid peptide [1, 3].

Who developed PNC-27?

It was designed by Matthew R. Pincus, Josef Michl and colleagues at SUNY Downstate Medical Center and the VA New York Harbor, with the founding paper published in 2001 [1].

Is PNC-27 FDA approved?

No. As of October 2026 PNC-27 is not FDA-approved, no human trial has been registered, and published research is preclinical only.

What is the difference between PNC-27 and PNC-28?

Both use the same penetratin-based leader. PNC-27 carries p53 residues 12–26, while PNC-28 carries the shorter residues 17–26 [2, 3].

Sources

  1. Kanovsky M, Raffo A, Drew L, Rosal R, Do T, Friedman FK, Rubinstein P, Visser J, Robinson R, Brandt-Rauf PW, Michl J, Fine RL, Pincus MR. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci USA. 2001;98(22):12438–12443. doi:10.1073/pnas.211280698. Link
  2. SUNY Downstate Health Sciences University. Faculty profile: Matthew R. Pincus, MD, PhD, Department of Pathology. Link
  3. Sarafraz-Yazdi E, Mumin S, Cheung D, et al., Bowne WB, Pincus MR, Michl J. PNC-27, a chimeric p53-penetratin peptide binds to HDM-2 in a p53 peptide-like structure, induces selective membrane-pore formation and leads to cancer cell lysis. Biomedicines. 2022;10(5):945. doi:10.3390/biomedicines10050945. Link
  4. Rosal R, et al., Pincus MR. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein. Biochemistry. 2004. PMID 14967026. Link
  5. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem. 1994;269(14):10444–10450. PMID 8144628. Link
  6. Sarafraz-Yazdi E, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci USA. 2010;107(5):1918–1923. doi:10.1073/pnas.0909364107. Link
  7. National Library of Medicine. MeSH Supplementary Concept Record C549751: PNC-27 (introduced 3 Jun 2010). Link
  8. World Anti-Doping Agency. 2026 Prohibited List. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top